Kirk D. Robarge
Genentech · 58 works · 2,327 citations · h-index 24
Top works
- Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance
- GDC-0449—A potent inhibitor of the hedgehog pathway
- From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold
- Accelerated inverse electron demand Diels-Alder reactions of 1-oxa-1,3-butadienes: [4 + 2] cycloaddition reactions of .beta.,.gamma.-unsaturated .alpha.-keto esters
- Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition
- Divergent de novo synthesis of carbohydrates based on an accelerated inverse electron demand Diels-Alder reaction of 1-oxa-1,3-butadienes
- Stereoselectivity in the electrophile-mediated cyclization of 2,3,5-tri-O-benzyl-1,2-dideoxy-d-arabino-hex-1-enitol. A stereocontrolled synthesis of 1-amino-2,5-anhydro-3,4,6-tri-O-benzyl-1-deoxy-d-glucitol
- Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
- Epimerization at C-2 during the Wittig reaction of 2,3,5-tri-O-benzyl-d-ribose and methylidenetriphenylphosphorane
- Mono-N-alkylation of anthranilamides via quinazolinones. An efficient synthesis of G5598, a benzodiazepine dione gpIIbIIIa antagonist
- Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor
- Electrophile-mediated cyclizations in carbohydrate chemistry: synthesis of highly functionalized ribofuranose and ribopyranose compounds
- From Peptide to Non-Peptide. 3. Atropisomeric GPIIbIIIa Antagonists Containing the 3,4-Dihydro-1H-1,4-benzodiazepine-2,5-dione Nucleus
- Electrophile-mediated cyclizations of 6-O-benzyl-1,2-di- deoxy-3,4-O-isopropylidene-d-ribo-hex-1-enitol to derivatives of 2,5-anhydro-6-O-benzyl-3,4-O-isopropylidene-d-altro-hexitol
- Discovery and preclinical development of vismodegib
- A Selective, Slow Binding Inhibitor of Factor VIIa Binds to a Nonstandard Active Site Conformation and Attenuates Thrombus Formation in Vivo
- Corrigendum to “GDC-0449—A potent inhibitor of the hedgehog pathway” [Bioorg. Med. Chem. Lett. 19 (2009) 5576]
- Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists
- Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase
- Preclinical Disposition of GDC-0973 and Prospective and Retrospective Analysis of Human Dose and Efficacy Predictions